Company has every right to re-evaluate technology to provide the best outcome for shareholders through improved products. Given the various tech platforms on hand through blended companies not sure why the ex-directors thought it was their God given right to have performance bonuses served on a platter. With the limited time constraints and prioritising other tech their claims certainly dont seem to align with biotech reality.
Ann: Update on Legal Proceedings and BARD1 Autoantibody Program, page-19
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
61.0¢ |
Change
0.020(3.39%) |
Mkt cap ! $67.26M | |||
| Open | High | Low | Value | Volume |
| 58.0¢ | 61.0¢ | 58.0¢ | $56.05K | 95.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2999 | 59.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 61.0¢ | 12999 | 3 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |